Syrup Group Research Articles

A COMPARISON OF ORAL ONDANSETRON SYRUP OR INTRAVENOUS ONDANSETRON LOADING DOSE REGIMENS GIVEN IN COMBINATION WITH DEXAMETHASONE FOR THE PREVENTION OF NAUSEA AND EMESIS IN PEDIATRIC AND ADOLESCENT PATIENTS RECEIVING MODERATELY/HIGHLY EMETOGENIC CHEMOTHERAPY

This double-blind, parallel-group, multicenter study compared the efficacy and safety of intravenous (IV) ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy. On each day of chemotherapy, patients were administered on dansetron 5 mg/m2 IV and placebo syrup orally ( n = 215) orondansetron 8 mg syrup orally and placebo IV ( n = 223) plus dexamethasone 2-4 mg PO. Ondansetron 4 mg syrup PO was administered twice daily for 2 days following the cessation of chemotherapy. Complete or major control of emesis was obtained in 89% patients in the IV group and 88% patients in the oral syrup group during the worst day of chemotherapy treatment (90% CI: 6, 4) and in 85% and 82% patients, respectively, during the worst day of the study period (90% CI: 8, 3). Intravenous ororal syrup ondansetron plus dexamethasone was well tolerated and effective in preventing chemotherapy-induced emesis in pediatric patients.

Chloroquine phosphate suppositories in the treatment of childhood malaria in Calabar, Nigeria

In a randomized, prospective study of the therapy of acute falciparum malaria in 69 children, aged 6 to 60 months, the results of treatment with chloroquine phosphate suppositories (30 patients) and chloroquine sulfate syrup (39 patients) were compared. Each pateint received 25-mg chloroquine base/kg body weight over 3 consecutive days (day 0, 10 mg/kg; day 1, 10 mg/kg; and day 2, 5 mg/kg). The parasitologic cure rate was 33% ( 10 30 ) in the chloroquine phosphate suppository group and 36% ( 14 39 ) in the chloroquine sulfate syrup group. In addition, the mean pretreatment parasite counts of the chloroquine-sensitive cases were not significantly different in the two groups. However, pyrexia resolved slightly more slowly in the suppository group, although all sensitive patients in both groups were aferible on day 3. The results suggest that chloroquine phosphate suppositories are as effective as chloroquine sulfate syrup in the treatment of children with malaria caused by chloroquine-sensitive Plasmodium falciparum.